Liza C. Villaruz - Concepedia

Author

Liza C. Villaruz

Also Known As

L Liza Villaruz, L Villaruz, L. Villaruz, L.C. Villaruz, Liza C Villaruz, Liza C. Villaruz, Liza Cosca Villaruz, Liza Villaruz, Nieva, Jorge, Weiss, Jared M.

211

Publications

6.5K

Citations

H-Index

Concepts

All Affiliations

UPMC Hillman Cancer Center University of Pittsburgh Medical Center Dana-Farber Cancer Institute Massachusetts General Hospital University of Colorado Denver

About

Liza C. Villaruz is an author at UPMC Hillman Cancer Center specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	1.8K
2	Health Sciences	6	6	495
3	Cell Biology	2	2	68
4	Engineering	1	1	65
5	Diagnostic Sciences	1	1	256

Liza C. Villaruz

Publications

3.3K

Citations

H-Index

Page 1

	Year	Citations
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration Alexander Drilon, Jeffrey W. Clark, Jared Weiss, Nature Medicine Lung CancersAntitumor ActivityMedicinePharmacologyPathology	2020	364
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski, Journal of Thoracic Oncology Neuro-oncologyAtezolizumab Plus BevacizumabMedicinePathologyCancer Treatment	2021	283
Efficacy and safety of crizotinib in patients with advanced <i>c-MET</i>-amplified non-small cell lung cancer (NSCLC). D. Ross Camidge, Sai‐Hong Ignatius Ou, Geoffrey I. Shapiro, Journal of Clinical Oncology PathologyPharmacotherapyPre-clinical PharmacologyMolecular PharmacologyMetronomic Therapy	2014	256
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis David Planchard, Benjamin Besse, Harry J.M. Groen, Journal of Thoracic Oncology	2021	253
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Journal of Clinical Oncology	2022	228
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial Jonathan D. Schoenfeld, Anita Giobbie‐Hurder, Srinika Ranasinghe, The Lancet Oncology MedicinePrevious PdBronchial NeoplasmImmune Checkpoint InhibitorCancer Treatment	2022	225
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2) Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry, Clinical Cancer Research	2017	212
Crizotinib in Patients With MET-Amplified NSCLC D. Ross Camidge, Gregory A. Otterson, Jeffrey W. Clark, Journal of Thoracic Oncology	2021	163
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement Liza C. Villaruz, Mark A. Socinski Clinical Cancer Research	2013	158
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp><i>BRAF</i></scp> mutations in the <scp>L</scp>ung <scp>C</scp>ancer <scp>M</scp>utation <scp>C</scp>onsortium Liza C. Villaruz, Mark A. Socinski, Shira Abberbock, Cancer	2014	122

Page 1